Articles tagged with Heart Failure
A cross-sectional study found that 15 million US adults have an elevated risk of heart failure (HF), with 4.3 million having low ASCVD risk but high HF risk. The study suggests hypertension control and weight loss as key interventions to reduce HF risk.
Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...
A new gene therapy has reversed the effects of heart failure in a large animal model by increasing blood pumping efficiency and dramatically improving survival rates. The therapy restored critical functions of heart cells and improved heart function on the microscopic level.
The American Heart Association has released its list of top cardiovascular research for 2024, focusing on prevention, treatment and the benefits of anti-obesity medications. The research highlights improvements in assessing cardiovascular risk, identifying early prevention opportunities and treating heart failure.
The American Heart Association has launched a new three-year initiative to standardize HCM systems of care and support better management of the disease. The initiative aims to overcome gaps in care for hypertrophic cardiomyopathy, leading to delayed treatment, increased risk of complications, and preventable death.
A new study suggests that using AI-ECG tools to screen patients for low ejection fraction is cost-effective in the long term, especially in outpatient settings. The study found a cost-effectiveness ratio of $1,651 per quality-adjusted life year, indicating that the program can reduce costs over time.
A study found that middle-aged women who engaged in short bursts of vigorous physical activity, such as carrying shopping or power walking, had a significantly lower risk of heart attacks and heart failure. Women who averaged 3.4 minutes of daily activity were 45% less likely to experience a major cardiovascular event.
Researchers assess 20 years of clinical trials for cell therapy's safety and efficacy in treating heart failure, highlighting progress despite challenges. The field continues to evolve through lessons learned from past studies, with ongoing trials taking novel directions.
Researchers found a novel link between aortic stenosis and insulin resistance, with certain biomarkers increasing the risk of the disease. The study's findings suggest that managing metabolic health could be a new approach to reduce the risk of AS and improve cardiovascular health in aging populations.
The Emory University Hospital team successfully implanted the BrioVAD System, a novel magnetically levitated pump designed for patient ease and long-term health. This marks the first-time use of the device in the US, as part of the INNOVATE clinical trial.
A recent study published in Circulation found a correlation between lower levels of coagulation factor XI and an increased risk of heart failure. The research, conducted on two large community-based cohorts, also linked lower factor XI levels to a greater likelihood of atrial fibrillation and worse heart function.
Researchers at Karolinska Institutet discovered that patients with heart pumps can regenerate heart muscle cells at a rate more than six times higher than in healthy hearts, offering new hope for therapies to stimulate the heart's ability to repair itself after damage.
A recent study published in the SUMMIT trial found that tirzepatide significantly reduced deaths and worsening heart failure in patients with diastolic heart failure and obesity. The drug also led to substantial weight loss and improvements in overall health and quality of life.
Researchers at UVA discovered the heart reacts to viral infections in one of three ways, with specific gene patterns indicating healing or damage. This finding may lead to better treatments for people at risk of heart failure and other chronic conditions linked to viral infections.
A nasal spray form of bumetanide has been found to reduce tissue swelling in heart failure as effectively as standard oral and intravenous formulations. This new treatment option could provide a valuable tool for treating heart failure, promoting care at home and reducing hospital admissions.
A new study by Intermountain Health found that 40% of newly diagnosed heart failure patients also have atrial fibrillation, leading to poorer outcomes. Patients with both conditions require more aggressive treatment and regular screenings.
Prescription rates of sodium-glucose cotransporter-2 inhibitors increased substantially within 2 years after publication of clinical trial evidence documenting benefit. The study highlights the need to understand strategies used by higher prescribing centers to increase SGLT2i adoption.
Studies published in JACC found that anti-obesity drugs such as tirzepatide and semaglutide improved cardiac structure and function, as well as reduced cardiac risk biomarkers with lifestyle interventions. These findings suggest that these treatments may have a transformative impact on cardiovascular health beyond weight loss.
Researchers found that sacubitril-valsartan, a commonly prescribed heart failure medication, can help prevent heart damage related to chemotherapy treatment among high-risk cancer patients. The study highlights the importance of identifying patients at high risk for heart damage and suggests strategies for early intervention.
The Finerenone Trial found finerenone to be effective in reducing the primary end point in both women and men with heart failure. Finerenone, a mineralocorticoid receptor antagonist, showed similar tolerability in women and men.
A large-scale clinical trial found that intravenous infusion of exenatide during heart surgeries involving bypass did not significantly reduce the risk of death, stroke, or organ failure. The study included approximately 1,400 adults and a randomized, double-blind, placebo-controlled design.
Research found that spironolactone reduced the likelihood of heart failure after a heart attack, but did not significantly reduce deaths or other severe heart-related events. The study included over 7,000 adults in 14 countries who had experienced a severe heart attack.
A study found that pharmacists who received feedback about their heart failure patients increased the frequency of their patient interactions and prescribed more medication adjustments. The intervention, which provided educational resources and monthly audit and feedback emails, led to a significant increase in heart failure management.
In patients with mildly reduced ejection fraction, finerenone resulted in more frequent hyperkalemia but maintained clinical benefit when dose-adjusted. With protocol-directed surveillance, finerenone showed improved clinical outcomes compared to placebo, even at high potassium levels.
Researchers studied heart failure patients in zero gravity to assess the impact on left ventricular filling pressures. They found that external constraint affects cardiac hemodynamics, leading to changes in blood pressure and potential new treatment avenues for heart failure management.
A recent study found that intensive systolic blood pressure reduction approaches can significantly reduce the risk of major cardiovascular events in adults with Type 2 diabetes. Lowering systolic blood pressure to less than 120mmHg led to a reduced risk of heart attack, stroke, and death from cardiovascular disease.
The international SUMMIT trial found tirzepatide lowered the risk of worsening heart failure events and cardiovascular death in obese adults with preserved ejection fraction. Participants experienced improved health status, physical function, and exercise tolerance compared to placebo.
A new study by Mass General Brigham researchers found that excessive sedentary behavior increases the risk of heart failure and cardiovascular death. Even among individuals who meet guideline levels of moderate-to-vigorous physical activity, sitting for extended periods can still pose significant health risks. The study's findings sugg...
A study of 89,530 participants found that more than 10.5 hours of sedentary behavior per day increases the risk of heart failure and cardiovascular death, even among those who meet recommended exercise levels. Replacing excessive sitting time with physical activity can lower heart health risks.
A new study found that pregnant people in Massachusetts who made multiple unscheduled hospital visits during pregnancy were more likely to experience severe maternal morbidity. The study revealed that nearly half of these patients visited multiple hospitals, leading to inconsistent treatment and poor maternal outcomes.
A diet rich in soybean protein β-conglycinin has been shown to increase short-chain fatty acid production, which plays a role in protecting the heart. Analysis of gut bacteria identified an increase in specific SCFA-producing bacteria, further supporting the potential benefits of soy on heart health.
Researchers used machine learning to analyze data from 50 CF-LVAD patients and identified six prognostic factors that predicted post-implantation stroke. Lower levels of OxPhos proteins were associated with an increased risk of new strokes after implantation.
A new study found that beta blockers, commonly used to treat heart attack patients with normal pumping function, may lead to increased depression symptoms. Researchers observed more severe depression symptoms in patients who received beta blockers compared to those who did not.
Dr. Jeffrey Popma joins CRF as Chief Scientific and Strategic Officer, bringing decades of clinical and research experience to drive forward pivotal programs and initiatives. His leadership will shape CRF's future and fuel innovation at the Clinical Trials Center.
A new study found that even moderate amounts of exercise can reduce the risk of atrial fibrillation, a common heart condition. The research, led by NYU Langone Health, used data from over 6,000 participants and showed that those with higher physical activity levels had a lower risk of developing the condition.
The American Heart Association has announced five health technology start-up companies as finalists in its 7th annual Health Tech Competition. The competition aims to drive technological advancements with the potential to transform heart and brain health patient outcomes.
Clinicians should avoid using 'never words' that can scare, offend, or diminish agency in patients and families dealing with serious illness. Researchers recommend alternative language and methods for clinicians to identify their own never words.
The American Heart Association has awarded $75,000 to local entrepreneurs to develop innovative solutions addressing health inequities in their communities. The EmPOWERED to Serve Business Accelerator program supports social entrepreneurs and organizations focused on improving health outcomes.
Symbiosis has developed an adjustable TMVR system, ValSync, which can adapt to complex anatomies. The company aims to overcome current limitations and improve patient eligibility, safety, and procedure time with its three-step process.
A study by Saint Louis University researchers found that only one in eight patients with heart failure in the US receive palliative care consultations. Black patients were 15% less likely to receive palliative care compared to white counterparts, highlighting significant racial disparities.
New research at Lund University reveals that heart transplant patients often suffer from long-term pain and symptom distress after the procedure. However, with simple support in symptom management, patients can regain control over their life and feel more competent, active, and confident. The study found that a person-centred approach,...
Researchers investigated the molecular mechanism of Fuzi's cardioprotective effects on heart failure. Fuzi water decoction and alkaloids were found to regulate apoptosis, proliferation, and anti-fibrosis in heart failure models, with ABC transporters potentially being a key pathway for their action.
The Impella ECP pivotal study demonstrated low complication rates and successful closure with a 92% success rate. The 9Fr size of the device provides circulatory support and left ventricular unloading for high-risk PCI procedures.
A new study from Karolinska Institutet reveals a decline in heart failure mortality in Sweden over the last 20 years. Despite improvements, the prognosis for heart failure patients remains concerning, with 25% of those diagnosed in 2022 dying within a year.
Researchers at UCLA have identified the protein GPNMB as a critical regulator in the heart's healing process after a heart attack. GPNMB promotes heart repair by binding to receptor GPR39, triggering a cascade of signals that limit scarring and improve cardiac function.
Scientists at UCLA have engineered an experimental therapy that shows promise in enhancing heart repair following a heart attack, preventing the onset of heart failure. The new single-dose therapy targets the protein ENPP1, which is responsible for increasing inflammation and scar tissue formation.
A new study suggests that immunotherapy may be an effective treatment strategy for heart failure by blocking scar tissue formation and improving heart function. Researchers identified a type of fibroblast cell responsible for scar tissue and used a monoclonal antibody to reduce its formation, showing promising results in mouse models.
Gladstone researchers have identified a complex molecular connection between immune cells and fibroblasts that contributes to fibrosis in the heart, which may lead to new treatments for heart disease and other fibrotic conditions.
The Cardiovascular Research Foundation recognizes 29 leading institutions for their contributions to groundbreaking research advancing interventional cardiovascular medicine. The 2024 SET-10 rankings celebrate institutions making significant impacts across various categories, including basic science and clinical research.
Researchers at Shinshu University developed a simple risk score model to predict successful weaning from mechanical circulatory support. The scoring method uses easily measurable health indicators, such as blood pressure and cardiac output, to categorize patients into five groups with varying success rates.
Researchers have identified a protein called PERM1 that regulates both energy and heart muscle contraction, offering a new therapeutic approach to systolic heart failure. By addressing the underlying problem of weakened heart muscle, PERM1 may help restore cardiac function and improve patient outcomes.
Researchers have found that women are more likely to die from postoperative complications after high-risk cardiovascular surgery, with a failure to rescue rate of 10.7% compared to 8.6% for men. The quality of hospital where the procedure was performed did not affect this disparity.
Cardiovascular diseases like heart failure and atrial fibrillation are linked to cognitive impairment and increased risk of dementia. Adopting a healthy lifestyle and identifying vascular risk factors early may help preserve brain function and reduce the burden of Alzheimer's disease.
Biomedical engineer Jeff Saucerman has received a $3.1 million NIH grant to study low-density lipoprotein receptor 1 and its impact on heart failure and treatment outcomes after a heart attack.
A new study identifies phosphatidylinositol 4,5-bisphosphate as a key regulator of the SK2 channel, which plays a critical role in cardiac ion channels and heart rhythm. The research provides critical translational insights into possible mechanisms of cardiac arrhythmias in heart failure.
Researchers found that heart transplant recipients from most deprived areas had a higher risk of dying within five years and experiencing organ failure compared to those from less deprived areas. Treatment at high-quality hospitals did not translate into better outcomes.
A nationwide Swedish study found that full vaccination significantly reduced the risk of severe cardiovascular outcomes linked to COVID-19, such as heart attack and stroke. However, temporary increases in cardiovascular risk were observed after individual doses, particularly among elderly and males.
A clinical trial found that mavacamten, a cardiac myosin inhibitor, reduced biomarkers of cardiac wall stress and injury in patients with heart failure. The treatment showed no significant reduction in left ventricular ejection fraction.
A Duke-NUS study proposes a new treatment for heart failure with preserved ejection fraction (HFpEF) by blocking glucagon's activity, which raises blood sugar levels. This breakthrough could provide quicker relief to millions of heart patients.
Long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone is estimated to extend event-free survival by up to 3 years among people with heart failure. The FINEARTS-HF randomized clinical trial found this benefit in patients with mildly reduced or preserved ejection fraction.